MaxCyte Investor Presentation Deck

Q2 2023 Key Financial Highlights Revenues ($M) $9.6M $1.9 $7.7 $9.0M $0.8 $1.7 Gross Margins ~85% $6.6 Q2 2022 Q2 2023 Cell Therapy Drug Discovery Program-related 19 Operating Expenses ($M) $17.2M M MaxCyte Q2 2022 $20.7M Q2 2023 Balance Sheet Total cash, cash equivalents and short-term investments were $216 million as of June 30, 2023 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation